Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Neoplasms 3Carcinoma, Hepatocellular 3Neoplasm Metastasis 2Glioma 2Glioblastoma 2Solid Tumor 1Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × LY-2157299 × Clear all
NCT01373164 2018-05-16

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Completed
170 enrolled 25 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02304419 2016-10-05

A Study of Galunisertib on the Immune System in Participants With Cancer

Eli Lilly and Company

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT01722825 2014-07-01

Study of LY2157299 in Japanese Participants With Cancer

Eli Lilly and Company

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡